Clinical trial NCT06305962: 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Official title: Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: PDL1 Gene Mutation
Non Small Cell Lung Cancer
Small Cell Lung Cancer ( SCLC )
TNBC, Triple Negative Breast Cancer
Cutaneous Melanoma
HNSCC
Endometrial Cancer
Keywords: PDL1 Positive
Non Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC)
TNBC, Triple Negative Breast Cancer
Cutaneous Melanoma
HNSCC
Endometrial cancer
Lead sponsor: Radiopharm Theranostics, Ltd
Sponsor class: INDUSTRY
First posted: 2024-03-12
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability, biodistribution, radiation dosimetry and preliminary anti-tumour activities of 177Lu-RAD204 in participants with selected solid tumours, to identify the MTDs/ recommended doses of 177Lu-RAD204 for future exploration.

The study will consist of a Pre-screening Period (if applicable for PD-L1 testing), a Screening Period of up to 4 weeks, followed by a Phase 0 (Imaging) Period for imaging and dosimetry to 177Lu-RAD204im and a Phase I (Treatment) Period for 177Lu-RAD204tr dose escalation.


Eligibility criteria: Inclusion Criteria:

1. Willing and able to provide informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.
2. Adult participants ≥ 18 years of age.
3. Participants with a documented history of histopathologically confirmed metastatic NSCLC, SCLC, TNBC, cutaneous melanoma, HNSCC, and endometrial cancer with documented disease progression during or after their most recent line of anticancer therapy. Participants must be refractory to or have refused standard of care therapy (including PD-1/PD-L1 inhibitors), or have no standard of care therapy available that is likely to provide clinical benefit.
4. Participants with PD-L1 positive NSCLC, SCLC, TNBC, cutaneous melanoma, HNSCC, and endometrial cancer:

   * If the participant tumour's PD-L1 expression status is unknown, PD-L1 positivity may be determined in a pre-screening step whereby the participant may be approached to provide written informed consent to have their tumour tissue undergo IHC testing as determined by a validated test (tumour tissue may be obtained from archived samples or from a freshly obtained biopsy).
   * Any number of prior treatment lines are allowed.
5. Must have at least 1 measurable target lesion according to RECIST version 1.1.
6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
7. Participants must have a life expectancy of ≥ 4 months in the opinion of the Investigator.
8. Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female participants will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. Female participants \< 50 years old who meet the criteria for post-menopausal status without previous surgical sterilisation should be considered for further investigation with luteinising hormone (LH) and follicle stimulating hormone (FSH) levels to confirm serological post-menopausal status.
9. WOCBP must agree to use a highly effective method of contraception during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 6 months after the last dose of 177Lu-RAD204tr, whichever occurs later. Acceptable methods of contraception are described in Section 13.3 of the Protocol.
10. Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 6 months after the last dose of 177Lu-RAD204tr, whichever occurs later. All male participants must agree to not donate sperm during the study and for 14 days after the last injection of 177Lu-RAD204im and/or 6 months after the last dose of Lu-RAD204tr, whichever occurs later. Acceptable methods of contraception are described in Section 13.3 of the Protocol.
11. Participants with previously treated brain metastases are eligible to participate if:

    * they are neurologically and radiologically stable (no evidence of progression by imaging; same imaging modality \[magnetic resonance imaging (MRI) or computed tomography (CT) scan\] must be used for each assessment) for at least 28 days prior to the first dose of 177Lu-RAD204,
    * do not require steroids to treat associated neurological symptoms, and
    * have no history of leptomeningeal disease or spinal cord compression.
12. For Phase I:

    * Participants must have positive lesion(s) by 177Lu-RAD204im SPECT/CT per central review as described in Image Review Charter, and
    * Participants without any positive lesion by 177Lu-RAD204im SPECT/CT, e.g. due to poor image quality, may be allowed to enrol on a case-by-case basis at the discretion of the Principal Investigator and in discussion with study Sponsor, provided the participant's tumour is known to express PD-L1.

Exclusion Criteria:

1. History of prior organ transplant.
2. Any other known, active malignancy, except for treated cervical intraepithelial neoplasia or non-melanoma skin cancer. Patients with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
3. Have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time point imaging procedures, etc.
4. Residual toxicity ≥ Grade 2 from prior anti-cancer therapy (except alopecia).
5. History of uncontrolled allergic reactions and/or known or expected hypersensitivity to protein therapeutics, 177Lu-RAD204 or any of its excipients.
6. Inadequate organ functions as reflected in laboratory parameters:

   * Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) \< 60 mL/min
   * Platelet count of \< 100 × 109/L
   * Absolute neutrophil count (ANC) \< 1.5 × 109/L
   * Haemoglobin \< 9 g/dL
   * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 × ULN, or \> 5 × ULN for patients with known liver metastases
   * Total bilirubin \> 1.5 × ULN, except for patients with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 × ULN
   * For participants not taking warfarin or other anticoagulants: international normalised ratio (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≤ 1.5 × ULN. Participants taking warfarin must be on a stable dose that results in a stable INR \< 3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
7. Patients requiring blood product transfusion within 4 weeks of first dose of 177Lu-RAD204tr are not eligible to participate.
8. Clinically significant cardiovascular disease including but not limited to:

   * Unstable angina
   * Acute myocardial infarction within 6 months prior to screening
   * New York Heart Association (NYHA) Class II or greater congestive heart failure (see Section 20.6)
   * Clinically significant abnormalities in rhythm, conduction or morphology on resting ECG (e.g. complete left bundle branch block, third degree heart block)
   * Uncontrolled hypertension
   * Known LVEF \< 50%
   * QTcF \> 470 msec for females and QTcF \> 450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome.
9. Participation in any other investigational trial at the time of informed consent signature.
10. Pregnant or lactating women.

    The following exclusion criteria applies to participants in Phase I:
11. Major surgery within 4 weeks prior to first dose of 177Lu-RAD204tr.
12. Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, within 28 days (or 5 half-lives for biologic/non-cytotoxic agents, whichever is shorter), prior to the first dose of 177Lu-RAD204tr.
13. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher immune-mediated AE.

    NOTE: endocrine immune-mediated AEs that are controlled with replacement therapy are allowed.
14. Has had or is scheduled to have major surgery \< 28 days prior to the first dose of 177Lu-RAD204tr.
15. Positive status for human immunodeficiency virus (HIV).
16. Active or chronic hepatitis B or C. Chronic hepatitis B or hepatitis C with undetectable viral loads on stable suppression therapy may be allowed on a case-by-case basis in discussion with study Sponsor.
17. Any medical condition which, in the opinion of the Investigator, places the participant at an unacceptably high risk for toxicities.
18. Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.

Primary outcomes:
measure: Time Activity Curves (TACs)
timeFrame: 72 hours
measure: Radiation dosimetry of Lu177-RAD204im
timeFrame: 72 hours
measure: Pharmacokinetics of 177Lu-RAD204im
timeFrame: 72 hours
measure: Biokinetics of 177Lu-RAD204im
timeFrame: 72 hours
measure: Safety and tolerability of 177Lu-RAD204tr
timeFrame: 6 weeks
measure: Recommended dose(s) of 177Lu-RAD204tr for future exploration
timeFrame: 6 weeks
Secondary outcomes:
measure: Safety and tolerability of a single dose of 177Lu-RAD204im
timeFrame: 6 weeks
measure: Recommended dose(s) of 177Lu-RAD204im for future exploration
timeFrame: 2 weeks
measure: Preliminary antitumor activity of 177Lu-RAD204tr
timeFrame: Up to 30 weeks
measure: Radiation dosimetry of 177Lu-RAD204tr
timeFrame: 72 hours
Other outcomes:
measure: Level of agreement between 177Lu-RAD204im and standard of care imaging
timeFrame: Up to 30 weeks
measure: Effect of 177Lu-RAD204im and 177Lu-RAD204tr on tumor markers
timeFrame: Up to 30 weeks
Locations:
city: Kingswood
country: Australia
facility: Nepean Hospital
state: New South Wales
city: Wollongong
country: Australia
facility: Wollongong Hospital
state: New South Wales
city: North Lakes
country: Australia
facility: Icon Cancer Centre North Lakes
state: Queensland
city: Southport
country: Australia
facility: Gold Coast University Hospital
state: Queensland
city: Adelaide
country: Australia
facility: Cancer Research SA (CRSA)
state: South Australia
city: Murdoch
country: Australia
facility: GenesisCare Murdoch
state: Western Australia
Study officials:
References: